Levosimendan Alpha-Medical (Levosimendan)

Levosimendan increases the sensitivity of cardiac troponin C to calcium, boosting contractile force without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing arterial and venous dilation that lowers cardiac workload.

The dosing regimen for Levosimendan is determined by the prescribing physician based on the patient’s clinical condition, weight, and response. Specific infusion rates and duration are individualized and should follow local guidelines and the product’s prescribing information.

Safety of Levosimendan during pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under specialist supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional inotropes such as dobutamine, Levosimendan provides calcium‑sensitizing inotropy without increasing intracellular calcium, which may reduce the risk of arrhythmias. Unlike phosphodiesterase inhibitors like milrinone, it also offers vasodilatory effects through potassium‑channel activation, giving a broader hemodynamic profile.

Levosimendan Alpha-Medical should be stored at ambient temperature, below 25 °C, protected from light and moisture. Keep the product in its original packaging until use and avoid exposure to extreme temperatures or direct sunlight.

Levosimendan is administered intravenously, typically as an initial loading infusion followed by a continuous maintenance infusion. The exact rate and duration are set by the treating physician and adjusted according to hemodynamic response and tolerability.

The most serious risks include severe hypotension, ventricular arrhythmias and myocardial ischemia. Patients should be closely monitored for sudden drops in blood pressure, abnormal heart rhythms and signs of chest pain during and after the infusion.

Levosimendan is contraindicated in patients with severe hypotension, obstructive cardiomyopathy, recent myocardial infarction, uncontrolled arrhythmias, or known hypersensitivity to the drug. Caution is also advised in severe renal or hepatic impairment.